Poolbeg Pharma
  • About
    • About
    • Leadership
  • Pipeline
    • Pipeline
    • POLB 001 Oncology
    • POLB 001 Influenza
    • Oral Encapsulated GLP-1
    • AI Programmes
  • Partnering
  • Insights
  • News & Media
    • Media Coverage
    • Media Library
    • Media Press Kit
  • Investors
    • Investors
    • Regulatory News & Email Alerts
    • Share Price Information
    • Presentations & Events
    • AIM Rule 26
    • Documents
    • Advisors
    • Corporate Governance
  • Careers
  • Contact

Post navigation

Positive outputs from lab-based analysis of RSV drug candidates identified using AI
Poolbeg prioritizes RSV drug candidates identified through AI-led program


Subscribe for RNS email alerts
  • Privacy Policy
  • Cookie Policy
Londonstockexchange Logo White 2

Traded on the London Stock Exchange | Ticker: POLB

Stay in touch



Latest Presentation

© 2026 Poolbeg Pharma

link

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Poolbeg Pharma
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Cookie Policy

More information about our Cookie Policy